The chairman of Sun Pharma will resign on August 29.

Israel Makov, the chairman of Sun Pharma, will leave the organisation following the annual general meeting on August 29, the firm said on Wednesday. Makov will resign because his term ends at the end of the month.

In 2012, Israel Makov was chosen to serve as the company’s chairman and a board member. For the past ten years, he has served as the organization’s leader.

Under Makov, the business grew into the fourth-largest speciality generic pharmaceutical company in the world, with revenues of $1.7 billion. It has a $5 billion annual revenue and operates in over 100 markets. Makov also served as the organization’s executive during the 2014 purchase of Ranbaxy. According to the business, he contributed to the development of Sun Pharma’s global pipeline strategy for specialised goods.

“I was privileged to be part of the exciting path of Sun Pharma becoming a big worldwide leader in the pharmaceutical business,” Israel Makov remarked. Working with Sun Pharma’s talented leaders, who took part in the company’s transformation and effectively oversaw the change process, was very enjoyable for me. I appreciate the trust and support of my coworkers as well as the entire Board and am pleased of what this amazing firm has done.


Leave a Reply

error: Content is protected !!
Open chat
WhatsApp Now